ArticlePloS one2015
Genetically and Phenotypically Distinct Pseudomonas aeruginosa Cystic Fibrosis Isolates Share a Core Proteomic Signature.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- The impact of modulator therapy on theProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Bridging bench and bedside: translational omics ofEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- T6SS mutants exploit itaconate to support infection of phagocytes.bioRxiv : the preprint server for biology · 2026Article
- Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans.Nature communications · 2025Article
- Potential role of lysine acetylation in the stepwise adaptation ofMicrobiology spectrum · 2025Article
- Rapid fingerprinting of bacterial species using nanocavities created on screen-printed electrodes modified by β-cyclodextrin.Sensors & diagnostics · 2023Article
- Proteomic Analysis of Human Sputum for the Diagnosis of Lung Disorders: Where Are We Today?International journal of molecular sciences · 2022Review
- A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.Antimicrobial agents and chemotherapy · 2022Article
- Genome-driven elucidation of phage-host interplay and impact of phage resistance evolution on bacterial fitness.The ISME journal · 2022Article
- A wide-ranging Pseudomonas aeruginosa PeptideAtlas build: A useful proteomic resource for a versatile pathogen.Journal of proteomics · 2021Article
- Proteomic profiling of clinical and environmental strains of Pseudomonas aeruginosa.Molecular biology reports · 2021Article
- From genotype to phenotype: adaptations ofMicrobial genomics · 2021Review
- Pseudomonas aeruginosa reverse diauxie is a multidimensional, optimized, resource utilization strategy.Scientific reports · 2021Article
- Phenazines as potential biomarkers of Pseudomonas aeruginosa infections: synthesis regulation, pathogenesis and analytical methods for their detection.Analytical and bioanalytical chemistry · 2020Review
- The Core Proteome of Biofilm-Grown ClinicalCells · 2019Article
- Proteome profiling of Pseudomonas aeruginosa PAO1 identifies novel responders to copper stress.BMC microbiology · 2019Article
- Catabolism of Nucleic Acids by a Cystic FibrosisFrontiers in microbiology · 2019Article
- Dual Transcriptomics of Host-Pathogen Interaction of Cystic Fibrosis IsolateFrontiers in cellular and infection microbiology · 2018Article
- Paucimannose-RichMolecular & cellular proteomics : MCP · 2017Article
- Virulence adaptations ofMicrobiology (Reading, England) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The opportunistic pathogen Pseudomonas aeruginosa is among the main colonizers of the lungs of cystic fibrosis (CF) patients. We have isolated and sequenced several P. aeruginosa isolates from the sputum of CF patients and compared them with each other and with the model strain PAO1. Phenotypic analysis of CF isolates showed significant variability in colonization and virulence-related traits suggesting different strategies for adaptation to the CF lung. Genomic analysis indicated these strains shared a large set of core genes with the standard laboratory strain PAO1, and identified the genetic basis for some of the observed phenotypic differences. Proteomics revealed that in a conventional laboratory medium PAO1 expressed 827 proteins that were absent in the CF isolates while the CF isolates shared a distinctive signature set of 703 proteins not detected in PAO1. PAO1 expressed many transporters for the uptake of organic nutrients and relatively few biosynthetic pathways. Conversely, the CF isolates expressed a narrower range of transporters and a broader set of metabolic pathways for the biosynthesis of amino acids, carbohydrates, nucleotides and polyamines. The proteomic data suggests that in a common laboratory medium PAO1 may transport a diverse set of "ready-made" nutrients from the rich medium, whereas the CF isolates may only utilize a limited number of nutrients from the medium relying mainly on their own metabolism for synthesis of essential nutrients. These variations indicate significant differences between the metabolism and physiology of P. aeruginosa CF isolates and PAO1 that cannot be detected at the genome level alone. The widening gap between the increasing genomic data and the lack of phenotypic data means that researchers are increasingly reliant on extrapolating from genomic comparisons using experimentally characterized model organisms such as PAO1. While comparative genomics can provide valuable information, our data suggests that such extrapolations may be fraught with peril.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.